|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00608933 |
RATIONALE: Educating health providers on talking with cancer patients about complementary and alternative medicine (CAM) may help encourage health providers to talk more often with cancer patients about the use of CAM.
PURPOSE: This randomized phase III trial is studying how well an education intervention works in encouraging health providers to talk with cancer patients about the use of CAM.
Condition | Intervention | Phase |
Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Procedure: educational intervention Procedure: observation |
Phase III |
MedlinePlus related topics: | Cancer |
Study Type: | Interventional |
Study Design: | Other, Randomized, Single Blind, Active Control |
Official Title: | CAM USE and Cancer |
Estimated Enrollment: | 1360 |
Study Start Date: | March 2008 |
Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm I (intervention):: Active Comparator
Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
|
Procedure: educational intervention
Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
|
Arm II (wait-list):: No Intervention
Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I are made available to the wait-list health providers.
|
Procedure: observation
Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I are made available to the wait-list health providers.
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Stratification is based on the number of health providers at each CCOP component site (< 3 health providers per component site vs 3 to 6 health providers per component site vs 7 to 9 health providers per component site vs 10 or more health providers per component site). The CCOP component sites are randomized to 1 of 2 intervention groups.
Health providers in both arms complete questionnaires at baseline and at 2 months to assess the effectiveness of the educational intervention, personal CAM use, and level of knowledge about CAM and to determine if they are asking patients about CAM use. Patients of the health providers also complete questionnaires at the same time points to assess personal CAM use before and after cancer diagnosis as well as the level of their interaction with health providers regarding CAM use.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Health provider meeting the following criteria:
Has regular contact with cancer patients by initially talking with patients, taking their histories, and conveying pertinent information to their physician at a participating CCOP site
Patient of a health provider at a participating CCOP site meeting the following criteria:
Current diagnosis of cancer including amyloidosis
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
M.D. Anderson Cancer Center |
National Cancer Institute (NCI) |
Principal Investigator: | Patricia A. Parker, PhD | M.D. Anderson Cancer Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000584715, MDA-2006-0198 |
First Received: | January 30, 2008 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00608933 |
Health Authority: | Unspecified |
|